Upcoming Meetings: CLIA quality control meeting
This article was originally published in The Gray Sheet
Executive Summary
CLIA quality control meeting: Centers for Disease Control and Prevention schedules meeting for Sept. 25-26 to discuss "Quality Control Issues Relevant to Regulations Under the Clinical Laboratory Improvement Amendments" at CDC headquarters in Atlanta. Items on the agenda include: "the ability of current test systems to assess the potential for error in the total testing process"; "processes to monitor the quality of clinical laboratory results over time"; and "processes to assess appropriate operator performance." The committee will hear input from industry reps on the first day and other health professionals the second day; comments will be considered by CDC in the development of final CLIA regs for quality control. For further information, contact CDC's Julie Wasil at 770/488-4651...
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: